ACTINIUM PHARMACEUTICALS INC (ATNM) Stock Price, Quote, News and Overview
NYSEARCA:ATNM - NYSE Arca - US00507W2061 - Common Stock - Currency: USD
ATNM Quote, Performance and Key Statistics
1.21
-0.04 (-3.2%)
The current stock price of ATNM is 1.21 USD. In the past month the price decreased by -14.18%. In the past year, price decreased by -82.34%.
ATNM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.09 | 306.02B | ||
| AMGN | AMGEN INC | 13.99 | 149.08B | ||
| GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
| ARGX | ARGENX SE - ADR | 318.82 | 36.23B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
| NTRA | NATERA INC | N/A | 20.02B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
| BIIB | BIOGEN INC | 7.2 | 17.36B |
Related stock screener links
About ATNM
Company Profile
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. The company is headquartered in New York City, New York and currently employs 49 full-time employees. The company went IPO on 2014-03-26. The firm is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The firm focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The firm holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
Company Info
ACTINIUM PHARMACEUTICALS INC
100 Park Ave., 23Rd Floor
New York City NEW YORK 10016 US
CEO: Sandesh Seth
Employees: 49
Company Website: https://www.actiniumpharma.com/
Investor Relations: https://ir.actiniumpharma.com/
Phone: 16466773870
ACTINIUM PHARMACEUTICALS INC / ATNM FAQ
What is the stock price of ACTINIUM PHARMACEUTICALS INC today?
The current stock price of ATNM is 1.21 USD. The price decreased by -3.2% in the last trading session.
What is the ticker symbol for ACTINIUM PHARMACEUTICALS INC stock?
The exchange symbol of ACTINIUM PHARMACEUTICALS INC is ATNM and it is listed on the NYSE Arca exchange.
On which exchange is ATNM stock listed?
ATNM stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for ACTINIUM PHARMACEUTICALS INC stock?
11 analysts have analysed ATNM and the average price target is 5.1 USD. This implies a price increase of 321.49% is expected in the next year compared to the current price of 1.21. Check the ACTINIUM PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ACTINIUM PHARMACEUTICALS INC worth?
ACTINIUM PHARMACEUTICALS INC (ATNM) has a market capitalization of 37.75M USD. This makes ATNM a Nano Cap stock.
How many employees does ACTINIUM PHARMACEUTICALS INC have?
ACTINIUM PHARMACEUTICALS INC (ATNM) currently has 49 employees.
What are the support and resistance levels for ACTINIUM PHARMACEUTICALS INC (ATNM) stock?
ACTINIUM PHARMACEUTICALS INC (ATNM) has a support level at 1.17 and a resistance level at 1.25. Check the full technical report for a detailed analysis of ATNM support and resistance levels.
Is ACTINIUM PHARMACEUTICALS INC (ATNM) expected to grow?
The Revenue of ACTINIUM PHARMACEUTICALS INC (ATNM) is expected to grow by 16957.1% in the next year. Check the estimates tab for more information on the ATNM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ACTINIUM PHARMACEUTICALS INC (ATNM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ATNM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ATNM, evaluating the profitability, health, valuation and growth aspects
- ACTINIUM PHARMACEUTICALS INC (ATNM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ACTINIUM PHARMACEUTICALS INC (ATNM) Sales and EPS estimates to see what analysts future expectations are.
- ACTINIUM PHARMACEUTICALS INC (ATNM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ACTINIUM PHARMACEUTICALS INC (ATNM) Insider and Institutional Ownership to learn about the owners and their transactions.
- ACTINIUM PHARMACEUTICALS INC (ATNM) Stock Chart to make your own analysis
- ACTINIUM PHARMACEUTICALS INC (ATNM) Latest news and press-releases to stay up to date.
Does ACTINIUM PHARMACEUTICALS INC (ATNM) stock pay dividends?
ATNM does not pay a dividend.
When does ACTINIUM PHARMACEUTICALS INC (ATNM) report earnings?
ACTINIUM PHARMACEUTICALS INC (ATNM) will report earnings on 2025-04-24.
What is the Price/Earnings (PE) ratio of ACTINIUM PHARMACEUTICALS INC (ATNM)?
ACTINIUM PHARMACEUTICALS INC (ATNM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.27).
What is the Short Interest ratio of ACTINIUM PHARMACEUTICALS INC (ATNM) stock?
The outstanding short interest for ACTINIUM PHARMACEUTICALS INC (ATNM) is 7.33% of its float. Check the ownership tab for more information on the ATNM short interest.
ATNM Technical Analysis
ATNM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ATNM. While ATNM seems to be doing ok healthwise, there are quite some concerns on its profitability.
ATNM Financial Highlights
Over the last trailing twelve months ATNM reported a non-GAAP Earnings per Share(EPS) of -1.27. The EPS increased by 30.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.73% | ||
| ROE | -116.74% | ||
| Debt/Equity | 0 |
ATNM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to ATNM. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 25.4% and a revenue growth 16957.1% for ATNM